Organogenesis Holdings (ORGO) Other Non-Current Assets (2017 - 2026)
Organogenesis Holdings (ORGO) recorded quarterly Other Non-Current Assets of $16.1 million in Q1 2026, up 75.26% quarter-over-quarter from $9.2 million in Q4 2025, and up 176.47% on a YoY basis from $5.8 million in Q1 2025.
Organogenesis Holdings (ORGO) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Organogenesis Holdings' Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $16.1 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 176.47% year-over-year to $16.1 million; the TTM figure through Mar 2026 stood at $16.1 million (up 176.47% YoY), while the FY2025 annual figure was $9.2 million, up 83.88% from the prior year.
- Other Non-Current Assets was $16.1 million for Q1 2026 at Organogenesis Holdings, up from $9.2 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $16.1 million in Q1 2026 to a low of $1.3 million in Q3 2023.
- Historically, Other Non-Current Assets has averaged $5.5 million across 5 years, with a median of $5.0 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets dropped 16.87% in 2023, then soared 358.58% in 2024.
- A 5-year view of Other Non-Current Assets shows it stood at $1.5 million in 2022, then soared by 294.08% to $6.0 million in 2023, then declined by 16.44% to $5.0 million in 2024, then soared by 83.88% to $9.2 million in 2025, then jumped by 75.26% to $16.1 million in 2026.
- The last three Other Non-Current Assets figures came in at $16.1 million (Q1 2026), $9.2 million (Q4 2025), and $14.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 1.79 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 351.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 233.20 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 3.45 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 73.60 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 295.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 59.36 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 47.63 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Organogenesis Holdings | 317.58 Mn | 225.48 Mn | 11.46 Mn | 16.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.13 Mn |
| Dec 31, 2025 | 9.20 Mn |
| Sep 30, 2025 | 14.41 Mn |
| Jun 30, 2025 | 8.73 Mn |
| Mar 31, 2025 | 5.83 Mn |
| Dec 31, 2024 | 5.01 Mn |
| Sep 30, 2024 | 5.01 Mn |
| Jun 30, 2024 | 5.85 Mn |
| Mar 31, 2024 | 6.71 Mn |
| Dec 31, 2023 | 5.99 Mn |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.39 Mn |
| Mar 31, 2023 | 1.46 Mn |
| Dec 31, 2022 | 1.52 Mn |
| Sep 30, 2022 | 1.59 Mn |
| Jun 30, 2022 | 1.67 Mn |
| Mar 31, 2022 | 1.47 Mn |
| Dec 31, 2021 | 1.54 Mn |
| Sep 30, 2021 | 1.61 Mn |
| Jun 30, 2021 | 605,000.00 |